CervoMed
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
20 Park Plz Ste 424, Boston, Massachuset...Phone Number
(617) 744-4400Website
www.cervomed.comRevenue
<$5 MillionStock Symbol
CRVOIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
2
1
1
1
1
About CervoMed
CervoMed is a clinical-stage biotechnology company focused on developing innovative therapies for age-related neurodegenerative and neurological disorders. The companys research is centered on targeting underlying disease mechanisms associated with neuroinflammation and neurodegeneration through the development of novel small-molecule treatments. Its lead therapeutic program is being investigated for multiple neurological conditions, including disorders that affect cognition, language, and motor function. Through clinical research and strategic development efforts, CervoMed aims to advance disease-modifying treatments that address significant unmet medical needs and improve outcomes for patients living with progressive brain disorders.Explore more
CervoMed Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is CervoMed your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on CervoMed recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when CervoMed launches new products
Check if CervoMed has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once CervoMed has new funding data
Congratulate Masked Content for being promoted to Masked Content at CervoMed
Check out if CervoMed is spiking on competitors!
CervoMed, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if CervoMed had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to CervoMed
Compare insights from companies similar to CervoMed, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
CervoMed is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
CervoMed is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about CervoMed.
CervoMed financials insights
Gather financial insights about CervoMed, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Share Placement
$149.4M
2026
Stock/Share Issuance
$10.5M
CervoMed Tech Stack
A closer look at the technologies used by CervoMed
Most Recent Scoops
Project
CervoMed has received clear regulatory feedback from the FDA, MHRA, and EMA confirming that the Clinical Dementia Rating Sum of Boxes (CDR-SB) is accepted as an approval endpoint for the registrational pathway of neflamapimod in Dementia with Lewy Bodies (DLB), with feedback from Japan also being received.
Clinical Operations
Project
presented data at the American Academy of Neurology in April demonstrating that neflamapimod produces a measurable MRI effect on the basal forebrain, including stabilization and volume increase of cholinergic neurons, with functional MRI data on the cholinergic system correlating with improvements on the CDR Sum of Boxes.
Project
CervoMed has designed a single Phase III registrational trial for neflamapimod in Dementia with Lewy Bodies (DLB) comprising 300 patients across two arms, with greater than 95% statistical power on the CDR-SB primary endpoint, an estimated cost of $50 to $60 million, and an expected timeline of two years from study start to top-line results.
Clinical Operations
Project
CervoMed has confirmed with the FDA that a single registrational study will suffice to support potential approval of neflamapimod in the Dementia with Lewy Bodies (DLB) indication, with the company currently the only program advancing into pivotal development in DLB using CDR-SB as the primary endpoint in an indication with no currently approved pharmacological treatments.
Medical Research, Pharmaceuticals
Project
Medical Research, Pharmaceuticals
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding CervoMed
Sign Up For FreeTo access detailed company insights
CervoMed is a clinical-stage biotechnology company focused on developing innovative therapies for age-related neurodegenerative and neurological disorders. The companys research is centered on targeting underlying disease mechanisms associated with neuroinflammation and neurodegeneration through the development of novel small-molecule treatments. I... Read More
